| Literature DB >> 32276339 |
Federica Vinciguerra1, Marco Graziano1, Maria Hagnäs1,2,3, Lucia Frittitta1,4, Andrea Tumminia1.
Abstract
Alzheimer's disease (AD) is the most common form of senile dementia, accounting for up to 70% of dementia cases. AD is a slowly progressive disease, which causes global mental deterioration by affecting various cognitive areas. A growing body of evidence has demonstrated that lifestyle habits and nutritional patterns could delay the natural course of the neurodegeneration process. There is no single dietary pattern unequivocally proven to prevent AD. Nevertheless, epidemiological data suggest that by adopting several dietary habits, especially if accompanied with a healthy lifestyle, the negative consequences of AD could potentially be delayed. Alongside with others, two specific eating patterns have been well investigated concerning their potential beneficial effect on cognitive status: the Mediterranean diet (MedDi) and the Ketogenic Diet (KD). Despite the different underlying mechanisms, both of them have demonstrated a fairly profitable role in reducing or delaying cognitive impairment. The aim of the present narrative review is to overview the existing research on the efficacy of MedDi and KD against AD-related cognitive decline, focusing on the proposed protective mechanisms of action. Although the current knowledge on this complex topic does not allow us, at this point, to make exhaustive conclusions, this information could be of help in order to better characterize the possible role of MedDi and KD as nonpharmacological therapies in the treatment of AD and, more generically, of neurodegenerative disorders.Entities:
Keywords: Alzheimer disease; Mediterranean; cognition disorders; diet; ketogenic
Mesh:
Year: 2020 PMID: 32276339 PMCID: PMC7231139 DOI: 10.3390/nu12041019
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Main characteristics of the Mediterranean and ketogenic diet eating patterns.
| Mediterranean Diet | Ketogenic Diet | ||
|---|---|---|---|
| Characteristics: dietary pattern rich in monounsaturated fatty acids and polyphenols (mainly from olive oil), polyunsaturated fatty acids (from fatty fish), antioxidants, vitamins and minerals (magnesium, potassium, calcium, iodine, zinc, selenium). | Characteristics: very high-fat and low-carbohydrate diet, (carbohydrate intake ≤10% of consumed energy). | ||
| Moderate to high consumption | Low consumption | High consumption | Avoided consumption |
|
Whole grains Vegetables Fruits Olive oil Olives/nuts/seeds Low-fat dairies Herbs/spices/garlic/onions Eggs White meat Fish/seafood Potatoes Legumes Red wine |
Salt Red meat Processed meat Sweets |
Meat Fish and seafood High-fat dairies |
Whole/refined grains Flour products Starchy vegetables Fruit juices Legumes Wines, beer, drinks with added sweeteners |
Evidence on association between Mediterranean diet and cognitive decline.
| Randomized Controlled Trials (RCT) | |||
|---|---|---|---|
| Study Names and Characteristics | Main Findings | Year | Reference |
| Nu-Age Study | Higher adherence to Mediterranean diet (MedDi) was related to a significant improvement in global cognition and episodic memory after 1 year in 1279 relatively healthy older adults. | 2018 | [ |
| Medley Study | Adherence to MedDi compared to usual diet had no beneficial effects on cognitive performances (executive functioning, speed of processing, memory, visual-spatial ability, and overall age-related cognitive performance) in 137 healthy older adults (6 months RCT). | 2016 | [ |
| Predimed Study | Mediterranean diet (MedDi) supplemented with olive oil or nuts and compared to low-fat diet is associated with improved cognitive function evaluated with neuropsychological tests among 447 cognitively healthy older women at high cardiovascular risk after 4.1 years. | 2015 | [ |
| Predimed-Navarra Study | MedDi supplemented with olive oil or nuts compared to low-fat diet is associated with improved cognitive function examined by Mini-Mental State Examination (MMSE) and Clock Drawing Test (CDT) in 522 patients at high vascular risk after 6.5 years. | 2013 | [ |
|
| |||
| Meta-analysis | Adherence to MedDi improves global cognition of healthy older adults in particular in terms of the following: delayed recall, working memory, processing speed, and reasoning. | 2017 | [ |
| Systematic review and meta-analysis (9 cohort studies) | Higher adherence to the MedDi is inversely associated with the developing of cognitive disorders. | 2017 | [ |
| Systematic review and meta-analysis (43 studies) | Higher adherence to MedDi and higher consumption of unsaturated fatty acids, antioxidants, and B vitamins decrease the risk of dementia. | 2016 | [ |
| Systematic review | Higher adherence to MedDi is associated with less cognitive decline, dementia, or AD, as shown by 4 of 6 cross-sectional studies, 6 of 12 longitudinal studies, 1 trial, and 3 meta-analyses. | 2015 | [ |
| Systematic review and meta-analysis (5 studies) | Higher adherence to the MedDi is associated with a reduced risk of developing mild cognitive impairment (MCI) and Alzheimer’s disease (AD), and a reduced risk of progressing from MCI to AD. | 2014 | [ |
| Systematic review | Higher adherence to MedDi is associated with better cognitive function and lower rates of cognitive decline and AD. | 2013 | [ |
|
| |||
| Cross-sectional study | Higher adherence to MedDi was independently associated with better cognitive function and lower risk of cognitive impairment in 5907 community-dwelling older adults. Higher scores were independently associated with significantly better cognitive status in a dose-response manner. | 2017 | [ |
| Cross-sectional study | MedDi adherence was positively associated with the MMSE score in elderly men ( | 2013 | [ |
| Cross-sectional study | AD and MCI patients had a lower adherence to the MedDi than healthy controls in Australian population (149 patients with AD, 98 with MCI, 723 healthy controls). | 2012 | [ |
| Case-control study | Higher adherence to the MedDi was the main predictor of AD status in a case-control study nested within a community-based cohort in New York (194 patients with AD vs. 1790 nondemented subjects). | 2006 | [ |
|
| |||
| Prospective cohort study | During a mean follow-up of 12 years there was no association between MedDi-like diet adherence and the development of cognitive dysfunction among 1138 elderly Swedish men. | 2015 | [ |
| Prospective Study | Long-term MedDi adherence was related to moderately better cognition, but not with cognitive change (16,058 women from the Nurses’ Health Study, aged 70 years or older, 6-years follow-up). | 2013 | [ |
| Cache County Study on Memory, Health, and Aging | Higher adherence to MedDi was associated with higher levels of cognitive function in elderly men and women over an 11-year period ( | 2013 | [ |
| Regards | Higher MedDi adherence was associated with lower incidence of cognitive impairment in 17,478 individuals (mean follow-up of 4 years). | 2013 | [ |
| PATH Through Life study | Adherence to MedDi was not found to be protective against cognitive decline. Conversely, an excess of caloric intake and a higher consumption of monounsaturated fats were predictive of MCI (1528 participants; follow-up period of 4 years). | 2012 | [ |
| Prospective cohort study | Higher MedDi adherence was associated with lower risk of incident MCI among 1233 nondemented individuals. The odds ratio of MCI was reduced with both high vegetable intake and high polyunsaturated fatty acid consumption. | 2010 | [ |
| Prospective cohort study | Higher adherence to MedDi was associated with slower decline of MMSE but no other cognitive tests and was not associated to the risk of incident dementia (1410 adults aged 65 or older, 5 years follow-up). | 2009 | [ |
| Longitudinal study | Higher adherence to the MedDi is associated with reduced risk of MCI, but also reduced risk of developing AD (1393 cognitively normal participants, mean follow-up of 4.5 years). | 2009 | [ |
| Prospective cohort study | Higher adherence to the MedDi and higher physical activity were independently associated with reduced risk for AD in 1880 community-dwelling elders (mean follow-up 5.4 years). | 2009 | [ |
| EPIC-Greece cohort | Adherence to the MedDi was not associated with MMSE score (732 individuals; follow-up period 6–13 years). Physical activity is a significant predictor of cognitive function in the elderly. Seed oil intake may adversely affect cognition. | 2008 | [ |
| Community-based clinical trial | A total of 2258 nondemented individuals in New York were prospectively evaluated every 1.5 years. Higher adherence to the MedDi was found to be associated with lower risk for AD. | 2006 | [ |
Figure 1Proposed protective mechanisms of Mediterranean diet on brain health and cognitive functions. Abbreviations: LDL, Low-Density Lipoprotein; ROS, Reactive Oxygen Species.
Evidence on association between ketogenic diet and cognitive decline.
| Animal Studies | |||
|---|---|---|---|
| Study characteristics | Main findings | Year | Reference |
| Murine model | Ketogenic Diet (KD) may be able to enhance cognitive functions. | 2018 | [ |
| Murine model | KD improves memory in aging mice. | 2017 | [ |
| Murine model | Ketones significantly suppress intracellular β-amyloid (Aβ) accumulation and improve learning and memory function in symptomatic murine model of AD. | 2016 | [ |
| Murine model | A ketone ester diet improves performance on learning and memory tests and reduces the amounts of Aβ and phospho-Tau in the brain in a mouse model of AD. | 2013 | [ |
| Murine model | KD enhances motor performance but not cognition and Aβ or Tau deposition in murine models of AD. | 2013 | [ |
| Murine model | KD reduces total Aβ levels in a mouse model of Alzheimer’s (AD) after 43 days. | 2005 | [ |
| Murine model | KD impaired visual–spatial learning, memory, and brain growth in immature rats | 2004 | [ |
|
| |||
| Pilot study | Modified KD is associated with increased cerebral perfusion and improvement of memory performance in older adults at risk for AD ( | 2020 | [ |
| Case report | KD improves cognitive assessment of a 71-year-old female, heterozygous for ApoE4 with a family history of AD and diagnosis of mild AD after 10 weeks. | 2019 | [ |
| Clinical trial | KD had no effect on vigilance, visual learning, and memory, working memory, and executive function ( | 2019 | [ |
| Clinical Study | KD improved immediate and delayed logical memory tests after 8 weeks and both digit-symbol coding test and immediate logical memory test after 12 weeks in 20 patients with mild-to-moderate AD. | 2019 | [ |
| Case report | KD improves cognitive assessment of a 57-year-old female previously diagnosed with comorbid mild cognitive impairment (MCI) and metabolic syndrome. | 2018 | [ |
| Single-arm pilot trial: Ketogenic Diet Retention and Feasibility Trial (KDRAFT) | KD supplemented with medium-chain triglyceride improves AD Assessment Scale-cognitive subscale (ADAS-cog) after 3 months. | 2018 | [ |
| Case report | Hyperketonemia induced by beta-hydroxybutyrate (B-OHB)-promoting ketone monoester induces cognitive improvement | 2015 | [ |
| Clinical trial | KD improves memory function in older adults with MCI ( | 2012 | [ |
| Clinical trial | Ketosis induced by oral daily administration of ketogenic compound AC-1202 determines a significant improvement in the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in E4(-) AD patients. | 2009 | [ |
| Clinical trial | Administration of medium-chain triglycerides facilitated cognitive performance on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) only in older adults with AD or MCI who were apolipoprotein E4(-) AD patients. | 2004 | [ |
Figure 2Proposed protective mechanism of ketogenic diet on brain health and cognitive functions. Abbreviations: ATP, Adenosine Triphosphate; AGEs, Advanced Glycosylated End-products; APP, Amyloid Precursor Protein; PPAR-γ, Peroxisome Proliferator-Activated Receptor gamma; ROS, Reactive Oxygen Species.